Antonio Dono

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6243756/publications.pdf

Version: 2024-02-01

1039880 1058333 35 308 9 14 citations h-index g-index papers 35 35 35 300 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma. Journal of Neuro-Oncology, 2022, 156, 353-363.	1.4	3
2	Metastatic Neoplasm Volume Kinetics Following 2-Stage Stereotactic Radiosurgery. World Neurosurgery, 2022, 161, e210-e219.	0.7	5
3	Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery, 2022, Publish Ahead of Print, .	0.6	O
4	Glioma and the gut–brain axis: opportunities and future perspectives. Neuro-Oncology Advances, 2022, 4, vdac054.	0.4	10
5	Early repeat resection for residual glioblastoma: decision-making among an international cohort of neurosurgeons. Journal of Neurosurgery, 2022, 137, 1618-1627.	0.9	4
6	Gut microbiome and neurocritically ill patients. Journal of Neurocritical Care, 2022, 15, 1-11.	0.4	0
7	Concordance between Ki‑67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. Molecular and Clinical Oncology, 2022, 17, .	0.4	3
8	Metastatic colorectal micropapillary carcinoma presenting as lymphangitic lung carcinomatosis. Clinical Journal of Gastroenterology, 2021, 14, 193-197.	0.4	0
9	Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. World Neurosurgery, 2021, 146, e755-e767.	0.7	7
10	Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?. Journal of Neuro-Oncology, 2021, 152, 163-172.	1.4	4
11	IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions. Current Oncology Reports, 2021, 23, 20.	1.8	18
12	Extent of resection and survival outcomes of geriatric patients with glioblastoma: Is there benefit from aggressive surgery?. Clinical Neurology and Neurosurgery, 2021, 202, 106474.	0.6	11
13	Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas. , 2021, 40, 98-107.		4
14	Commentary: The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma. Neurosurgery, 2021, 89, E66-E67.	0.6	0
15	PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2021, 153, 153-160.	1.4	20
16	Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. World Neurosurgery, 2021, 149, e894-e912.	0.7	5
17	RADI-05. Metastatic Neoplasm Volume Kinetics Following Two-Staged Stereotactic Radiosurgery. Neuro-Oncology Advances, 2021, 3, iii18-iii19.	0.4	0
18	Molecular Alterations in Meningioangiomatosis Causing Epilepsy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1043-1051.	0.9	3

#	Article	IF	CITATIONS
19	Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma. Journal of Neuro-Oncology, 2021, 152, 153-162.	1.4	5
20	The role of <i>RB1</i> alteration and 4q12 amplification in IDH-WT glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab050.	0.4	5
21	Differences in Genomic Alterations Between Brain Metastases and Primary Tumors. Neurosurgery, 2021, 88, 592-602.	0.6	19
22	Predictors of outcome in pleomorphic xanthoastrocytoma. Neuro-Oncology Practice, 2021, 8, 222-229.	1.0	5
23	Treatment trends and overall survival in patients with grade II/III ependymoma: The role of tumor grade and location. Clinical Neurology and Neurosurgery, 2020, 199, 106282.	0.6	9
24	Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. Journal of Neuro-Oncology, 2020, 149, 463-472.	1.4	10
25	Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters. CNS Oncology, 2020, 9, CNS57.	1.2	19
26	Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors. Scientific Reports, 2020, 10, 14326.	1.6	14
27	Glioma and temozolomide induced alterations in gut microbiome. Scientific Reports, 2020, 10, 21002.	1.6	38
28	Letter to the Editor Regarding "The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007–2017― World Neurosurgery, 2020, 140, 422.	0.7	1
29	Real-time intracranial pressure monitoring during high-dose methotrexate treatment for primary central nervous system lymphoma. Cancer Treatment and Research Communications, 2020, 25, 100234.	0.7	3
30	Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics. Journal of Clinical Neuroscience, 2020, 82, 1-8.	0.8	22
31	Endoscopic Third Ventriculostomy for Hydrocephalus Secondary to Extraventricular Obstruction in Thalamic Hemorrhage: A Case Series. Operative Neurosurgery, 2020, 19, 384-392.	0.4	3
32	Molecular characteristics and clinical features of multifocal glioblastoma. Journal of Neuro-Oncology, 2020, 148, 389-397.	1.4	25
33	Landscape of Genomic Alterations in <i>IDH</i> Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor. JCO Precision Oncology, 2020, 4, 575-584.	1.5	15
34	Increased Risk of Subsequent Meningioma Among Women with Malignant Breast Cancer. World Neurosurgery, 2020, 139, e271-e285.	0.7	6
35	Immunotyping of tumorâ€ʻinfiltrating lymphocytes in tripleâ€ʻnegative breast cancer and genetic characterization. Oncology Letters, 2020, 20, 1-1.	0.8	12